Compare AdaptHealth Corp (AHCO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AdaptHealth Corp vs Sana Biotechnology Inc — how do they compare? AdaptHealth Corp trades at $5.72 (market cap $753.09M), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Sana Biotechnology Inc is the larger of the two by market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, AdaptHealth Corp nearer its low. Which is the better fit depends on your goals.
| AHCO | SANA | |
|---|---|---|
Market Cap | $753.09M | $1.13B |
Sector | Health | Health |
52-Week High | $13.38 | $5.92 |
52-Week Low | $5.22 | $2.68 |
Enterprise Value | $2.77B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $5.77, up 10.54% today but remains under significant pressure following recent earnings disappointments. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal revenue growth but negative profitability margins. Recent news highlights multiple securities fraud investigations and a strategic shift through the sale of its diabetes unit to focus on sleep and respiratory care.
Despite 75% analyst buy ratings and an $11 consensus price target suggesting substantial upside, immediate risks are elevated. The company faces execution challenges with fixed-price contracts, ongoing legal scrutiny, and consecutive earnings misses. Investors must weigh the potential recovery against substantial operational and legal headwinds.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AdaptHealth Corp
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
